Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
CAMBRIDGE, Mass. and TOKYO, February 28, 2017 -- Affinivax, Inc. ("Affinivax") and Astellas Pharma Inc. ("Astellas") today announced they have entered into an exclusive worldwide license agreement...
Kyowa Pharmaceutical Industry Co., Ltd. (Head office: Yodogawa-ku, Osaka City, President and Representative Director: Ray Tsunoda, hereinafter called “Kyowa”) and Astellas Pharma Inc....
Tokyo, February 23, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that Astellas, Takeda Pharmaceutical Company Limited (President and CEO:...
Tokyo, January 31, 2017 – Astellas Pharma Inc. (“Astellas”; Head Office: Tokyo, President and CEO: Yoshihiko Hatanaka) today announced that it executed a license agreement with respect to an...
TOKYO & CAMBRIDGE, Mass., Jan. 30, 2017 — Astellas Pharma Inc. (TSE: 4503) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today top-line results indicating that the Phase III...
Tokyo, January 18, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced its participation in Access Accelerated, a global, multi-stakeholder...
Tokyo, January 12, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announces that it will launch the second phase of the ongoing campaign with CNN....
Tokyo, January 10, 2017 - Astellas Pharma Inc. (TSE:4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) announced that it exercised its right to terminate the agreement executed as of...
Tokyo, December 26, 2016 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka) announced that it completed acquisition of its own shares, which was resolved by its Board of...
Tokyo, December 21, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has completed the acquisition of Ganymed Pharmaceuticals...
TOKYO (Dec. 20, 2016) – Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; General Manager and Representative Director: Mark Tennyson, “Amgen Astellas”) and Astellas Pharma Inc....
Tokyo, December 20, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) and Immunomic Therapeutics, Inc. (Founder & CEO: William Hearl, Ph.D., “Immunomic...
Tokyo, December 19, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that it obtained a marketing approval for a guanylate cyclase-C (GC-C)...
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu), Astellas Pharma Inc. (HQ: Tokyo, Japan; President and CEO: Yoshihiko Hatanaka) and Daiichi Sankyo Co., Ltd. (HQ: Tokyo,...
TOKYO and CHERTSEY – 12 December, 2016: Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”), today announced that Astellas Pharma Europe Ltd. (“Astellas Pharma...
Tokyo, December 7, 2016 - Astellas Pharma Inc. (TSE: 4503; President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that it launched Kiklin® Granules 86.2% (generic name: bixalomer,...
Tokyo, November 30, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) is promoting its strategic goal “Pursuing Operational Excellence” and engaged...
Follow us
